0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Invited Commentary | 
Eric K. Nakakura, MD, PhD
JAMA Surg. 2014;149(5):466. doi:10.1001/jamasurg.2013.5282.

Original Investigation | 
Raymond F. Lamore III, PharmD; Elizabeth M. Hechenbleikner, MD; Christina Ha, MD; et al.
JAMA Surg. 2014;149(5):459-466. doi:10.1001/jamasurg.2013.5278.

Sign in

Purchase Options

• Subscribe to the journal

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Viewpoint  | 
The Cost and Value of Anti–Epidermal Growth Factor Receptor Therapies:  Let's Not Be Rash
Leonard B. Saltz, MD
JAMA Internal Medicine
Invited Commentary  | 
Evidence-Based Deprescribing of Statins in Patients With Advanced Illness
Holly M. Holmes, MD, MS; Adam Todd, PhD, MPharm
JAMA Internal Medicine
Original Investigation  | 
Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness:  A Randomized Clinical Trial
Jean S. Kutner, MD, MSPH; Patrick J. Blatchford, PhD; Don H. Taylor, PhD; et al.
JAMA Internal Medicine
Special Communication  | 
Reducing Inappropriate Polypharmacy:  The Process of Deprescribing
Ian A. Scott, MBBS, FRACP, MHA, MEd; Sarah N. Hilmer, MBBS, FRACP, PhD; Emily Reeve, BPharm (Hons), PhD; et al.